Literature DB >> 19822700

Comparative efficacies of two antimony regimens to treat Leishmania braziliensis-induced cutaneous Leishmaniasis in rhesus macaques (Macaca mulatta).

G Grimaldi1, R Porrozzi, K Friedrich, A Teva, R S Marchevsky, F Vieira, N Miekeley, F J R Paumgartten.   

Abstract

This study compared the efficacies of two N-methylglucomine antimoniate (MA) dose regimens for treating macaques with Leishmania braziliensis-induced chronic skin disease. Whereas all animals treated with the full dose (20 mg MA/kg/day) were cured, 50% of the monkeys receiving a low-dose regimen (5 mg MA/kg/day) relapsed. The antimony concentrations in macaque plasma and tissue samples were greater in the full-dose group than in that receiving a subtherapeutic MA regimen. Our data also suggest the presence of drug-induced hepatic pathology.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19822700      PMCID： PMC2798537          DOI： 10.1128/AAC.00858-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs.

Authors:  Simon L Croft; Graham H Coombs
Journal:  Trends Parasitol       Date:  2003-11

2.  Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate.

Authors:  J D Chulay; L Fleckenstein; D H Smith
Journal:  Trans R Soc Trop Med Hyg       Date:  1988       Impact factor: 2.184

3.  Renal clearance of pentavalent antimony (sodium stibogluconate).

Authors:  P H Rees; M I Keating; P A Kager; W T Hockmeyer
Journal:  Lancet       Date:  1980-08-02       Impact factor: 79.321

4.  Characteristics of multidrug resistance in Plasmodium and Leishmania: detection of P-glycoprotein-like components.

Authors:  M Grogl; R K Martin; A M Oduola; W K Milhous; D E Kyle
Journal:  Am J Trop Med Hyg       Date:  1991-07       Impact factor: 2.345

5.  Monitoring of total antimony and its species by ICP-MS and on-line ion chromatography in biological samples from patients treated for leishmaniasis.

Authors:  N Miekeley; S R Mortari; A O Schubach
Journal:  Anal Bioanal Chem       Date:  2001-12-21       Impact factor: 4.142

6.  Leishmania spp.: development of pentostam-resistant clones in vitro by discontinuous drug exposure.

Authors:  M Grögl; A M Oduola; L D Cordero; D E Kyle
Journal:  Exp Parasitol       Date:  1989-07       Impact factor: 2.011

7.  Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate.

Authors:  Adriana Cruz; Petrie M Rainey; Barbara L Herwaldt; Grazia Stagni; Ricardo Palacios; Rodolfo Trujillo; Nancy G Saravia
Journal:  J Infect Dis       Date:  2007-01-11       Impact factor: 5.226

Review 8.  The utility of rhesus monkey (Macaca mulatta) and other non-human primate models for preclinical testing of Leishmania candidate vaccines.

Authors:  Gabriel Grimaldi
Journal:  Mem Inst Oswaldo Cruz       Date:  2008-11       Impact factor: 2.743

Review 9.  Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies.

Authors:  J D Berman
Journal:  Rev Infect Dis       Date:  1988 May-Jun

10.  Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.

Authors:  Rilza B Gayoso Azeredo-Coutinho; Sergio C F Mendonça; Heather Callahan; Andréia C Portal; Grögl Max
Journal:  J Parasitol       Date:  2007-06       Impact factor: 1.276
View more
  5 in total

1.  Leishmanicidal effect of antiparasitic photodynamic therapy-ApPDT on infected macrophages.

Authors:  Susana de Oliveira; Evaristo João da Ordem Trahamane; Juliana Monteiro; Gustavo Pires Santos; Pedro Crugeira; Fernando Sampaio; Camila Oliveira; Manoel Barral Neto; Antônio Pinheiro
Journal:  Lasers Med Sci       Date:  2017-07-27       Impact factor: 3.161

2.  Clinical Presentation and Response to Therapy in Children with Cutaneous Leishmaniasis.

Authors:  Carvel Suprien; Paulo N Rocha; Marina Teixeira; Lucas P Carvalho; Luiz H Guimarães; Toby Bonvoisin; Paulo R L Machado; Edgar M Carvalho
Journal:  Am J Trop Med Hyg       Date:  2020-04       Impact factor: 2.345

3.  Hepatotoxicity of pentavalent antimonial drug: possible role of residual Sb(III) and protective effect of ascorbic acid.

Authors:  Kelly C Kato; Eliane Morais-Teixeira; Priscila G Reis; Neila M Silva-Barcellos; Pascal Salaün; Paula P Campos; José Dias Corrêa-Junior; Ana Rabello; Cynthia Demicheli; Frédéric Frézard
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

4.  Low versus high dose of antimony for American cutaneous leishmaniasis: A randomized controlled blind non-inferiority trial in Rio de Janeiro, Brazil.

Authors:  Mauricio Naoto Saheki; Marcelo Rosandiski Lyra; Sandro Javier Bedoya-Pacheco; Liliane de Fátima Antônio; Maria Inês Fernandes Pimentel; Mariza de Matos Salgueiro; Érica de Camargo Ferreira E Vasconcellos; Sonia Regina Lambert Passos; Ginelza Peres Lima Dos Santos; Madelon Novato Ribeiro; Aline Fagundes; Maria de Fátima Madeira; Eliame Mouta-Confort; Mauro Célio de Almeida Marzochi; Cláudia Maria Valete-Rosalino; Armando de Oliveira Schubach
Journal:  PLoS One       Date:  2017-05-30       Impact factor: 3.240

5.  CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis.

Authors:  Seth G Thacker; Ian L McWilliams; Beatrice Bonnet; Lydia Halie; Serge Beaucage; Swaksha Rachuri; Ranadhir Dey; Robert Duncan; Farrokh Modabber; Stephen Robinson; Graeme Bilbe; Byron Arana; Daniela Verthelyi
Journal:  PLoS Negl Trop Dis       Date:  2020-02-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.